Akèy › Kasinom Selil Transizyonèl (Urotelyal) › Kalifòni › Orange
Etid klinik pou Kasinom Selil Transizyonèl (Urotelyal) nan Orange, CA
10 etid pou Kasinom Selil Transizyonèl (Urotelyal) ap chèche patisipan nan sit nan ak bò kote Orange (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Ap rekriteFaz 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Ap rekriteFaz 1/2
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Ap rekriteFaz 1/2
- UC Irvine Health, Orange
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Ap rekriteFaz 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Ap rekriteFaz 3
- UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Ap rekriteFaz 1 bonè
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Ap rekriteFaz 2
- UC Irvine Health, Orange
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Ap rekriteFaz 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Orange
Etid Kasinom Selil Transizyonèl (Urotelyal) nan lòt vil
- Nashville, TN23 etid
- New York City, NY22 etid
- Houston, TX19 etid
- Dallas, TX18 etid
- Edison, NJ18 etid
- Los Angeles, CA17 etid
- Queens, NY15 etid
- Chicago, IL14 etid
- Arlington, VA12 etid
- Boston, MA11 etid
- San Antonio, TX11 etid
- Austin, TX10 etid
Lòt etid nan Orange
- Kansè Poumon ki pa ti selil25 etid
- Kansè Metastatik20 etid
- Kansè kolorektal16 etid
- Kansè ovè16 etid
- Kansè pankreyas15 etid
- Melanom14 etid
- Kansè fwa (Kasinòm epatoselilè)14 etid
- Kansè nan tete14 etid
- Kansè poumon14 etid
- Kansè pwostat14 etid
- Kansè lestomak13 etid
- Kansè (tout kalite)13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.